Long-term Effectiveness of COVID-19 Vaccines Against Symptomatic and Asymptomatic Infection in the General Population and in Populations at Increased Risk for COVID-19
ArchivedCenters for Disease Control and Prevention - ERA
Description
The purpose of this notice of funding opportunity (NOFO) is to support research to evaluate the long-term effectiveness of COVID-19 vaccines against symptomatic and asymptomatic infections through long-term follow-up of vaccinated individuals (adults and children) and to assess immune response metrics, symptoms, and the development of asymptomatic infection/viral shedding. Studies should be adequately powered to generate product- and variant-specific vaccine effectiveness estimates and to assess risk factors for vaccine breakthrough, including demographic, immunologic, and virologic risk factors, where possible.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- Others
Contact
- PostedJul 21, 2021
- Award floor$3,000,000
- Award ceiling$4,000,000
- Program funding$60,000,000
- Expected awards3
- CFDA93.083
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro